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Abstract
This Special Section of the International Journal of Neuropsychopharmacology highlights current progress in
paediatric neuropsychopharmacology. Combining critical reviews and, in some cases, new data, specific topics
include : biological findings in major depression, sleep dysregulation in depressed youth, cardiovascular and
ventilatory dysregulation in panic disorder, paediatric autoimmune neuropsychiatric disorder associated with
strep (PANDAS), age of onset as a subtype marker in tic and obsessive–compulsive disorders (OCD), functional
and pharmaconeuroanatomy of OCD and the behavioural pharmacokinetics of methylphenidate. In this
introductory section, these articles are placed in the context of the state-of-the field and, more specifically,
within the framework of recent NIMH initiatives in paediatric neuropsychopharmacology.
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Introduction to the Special Section
While much remains to be learned (Jensen et al., 1999b ;
Vitiello, 1998), it is clear that the revolution in behavioural
neuroscience that has transformed adult psychiatry is now
reaching across stages of development to encompass child
and adolescent psychiatry (Hyman, 2000). In fact, many
adult psychiatrists are pursing collaborative relationships
with paediatric colleagues precisely because the epidemio-
logical data now suggests that adult mental illness has
its roots in childhood, which implies that early identifi-
cation provides an opportunity for prevention of lifelong
neuropsychiatric morbidity and mortality (Vitiello and
Jensen, 1997). Much work remains to be done before
promise becomes clinical practice (Norquist and Hyman,
1999). This Special Section of IJNP arose as an outgrowth
of discussions concerning recent progress in paediatric
neuropsychopharmacology between one of the guest
editors of the Special Section (Dr March) and the Editor of
IJNP (Professor Bernard Lerer) at the 1999 Regional
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Meeting of CINP in Asuncion, Paraguay. While not even
remotely comprehensive – recent textbooks provide a
more detailed yet already out-of-date view of advances in
paediatric neuropsychiatry (Coffey and Brumback, 1998 ;
Harris, 1995) – the Special Section should introduce the
reader to some of the newer and more interesting
developments in behavioural neuroscience that inform
modern paediatric neuropsychiatry.
Considerable research among adults implicates poor
regulation of emotional responses in risk for various
cardiovascular diseases. Much like many psychiatric
disorders, some cardiovascular diseases are considered
developmental conditions, with their roots in childhood
(Gerber and Stern, 1999). Among adults, deficient regu-
lation of the autonomic nervous system has been linked to
both emotional disorders and cardiovascular conditions.
Research specifically documents an association between
panic attacks and sudden death in adults (Gorman and
Sloan, 2000). As abnormalities in heart period variability
are linked to both sudden death and acute episodes
of anxiety, such as panic attacks, abnormalities in
heart period variability may at least partially explain
associations between some emotional and cardiovascular
conditions. In this context, Catherine Monk working in
the laboratory of Danny Pine, formerly of Columbia
University and now heading the paediatric division of the
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newly formed NIMH intramural Program in Mood and
Anxiety Disorders headed by Dennis Charney, examines
the association between paediatric anxiety and autonomic
dysregulation, as reflected in heart rate variability profiles
(Monk et al., 2001). In children, as in adults, they report
that anxiety is associated with subtle abnormalities in
autonomic regulation. Such findings carry implications for
developmental models of both cardiovascular as well as
emotional disorders. In turn, this suggests that the
relationship between childhood anxiety and adult panic is
nosologically complex or, stated differently, that the 30
year effort to force adult diagnostic criteria downward in
age to children and adolescents is fraught with problems,
especially given the high rates of comorbidity among
childhood onset anxiety disorders (Angold et al., 1999).
Beginning with the pioneering studies of Kim Puig-
Antich (Geller and Ryan, 1992), no centre has contributed
more to the understanding of biological factors in
paediatric affective illness than the Child Psychiatry
Group at Western Psychiatric Institute and Clinics
(WPIC). Summarizing 30 years of progress, much of it at
WPIC, and introducing new information regarding
dysregulation of growth hormone regulation in youth at
risk for depression, Pedro Heydl and Boris Birmaher
review the literature on biological markers in paediatric
depressive disorders (Birmaher and Heydl, 2001). Their
summary of neuroendocrine, serotonergic and sleep
probes suggests that, while there are unique devel-
opmental, age, severity, and exposure to stress factors
that alter the nature and course of affective illness in
youth, the psychobiology of childhood depression is not
all that dissimilar in the aggregate from that seen in adults.
With Birmaher and Heydl’s review providing a
heuristically valuable and historically important context,
Graham Emslie and colleagues from the University of
Texas, Dallas Southwestern, then go on to provide a
state-of-the-art summary of the literature on sleep in
depressed children and adolescents, concluding that
depressed children and adolescents exhibit less sleep
continuity and non-REM sleep differences in comparison
with control subjects than do adults (Emslie et al., 2001).
Importantly, they note that results from adult sleep
polysomnography studies cannot necessarily be
generalized to children and adolescents. They then
provide new data suggesting that sleep continuity
variables, specifically sleep efficiency and prolonged sleep
latency, are more disrupted in youth who exhibit early
recurrent depression than those who remain well. As
recently as 1998, Harrington and colleagues comment
with specific reference to depression that ‘ the focus
remains on treating ill youth and likely will until further
research offers us the opportunity of more targeted
prevention ’ (Harrington and Clark, 1998). Once replicated
and extended, the work by Emslie et al. (2001) offers the
promise of readily available clinically relevant poly-
somnographic markers for both length of treatment and
perhaps even the need for long-term pharmacological
treatment in depressed youth.
As in adults, OCD in youth is a relatively common and
chronically disabling illness that typically begins in
childhood and extends into adulthood in as many as two-
thirds of all cases (March and Leonard, 1996). Several lines
of evidence suggest that age of onset (early vs. late) or
comorbidity, especially with the tic disorders, or both,
may represent in phenomenology a neurobehavioural
subtype of OCD (Zohar, 1999 ; Zohar et al., 1997). In a
large sample of clinically referred youth with OCD, Geller
and colleagues (Geller et al., 2001) provide evidence that
externalizing, tic and anxiety disorders, but not mood or
psychotic disorders, show an early onset pattern
associated with OCD. Taking a different perspective on
early onset OCD, Henrietta Leonard formerly at the
NIMH and now at Brown University and Sue Swedo,
Director of the Pediatrics & Developmental Neuro-
psychiatry Branch at the NIMH, summarize their exciting
albeit controversial (in the sense that all truly interesting
science is controversial at the outset) attempt to define an
infectious disease model for early onset OCD (Kurlan,
1998 ; Leonard and Swedo, 2001 ; Trifiletti and Packard,
1999). Lead from inception to current understandings by
leading-edge researchers at the NIMH (Garvey et al.,
1998), paediatric autoimmune neuropsychiatric disorders
associated with strep (PANDAS) will likely yield the first
empirical demonstration of an aetiopathogenically defined
subtype of OCD and tic disorders. Unlike schizophrenia,
where neuroimmunological models remain mired in
aetiopathogenic controversy (Watson et al., 1999), the
evidence supporting the existence of PANDAS (if not its
prevalence or phenomenological boundaries) is gaining
increasing empirical support. Amazingly, some have even
speculated that PANDAS may lead to revision of the
Jones criteria for rheumatic fever to include post-
streptococcal OCD or tic disorders (Asbahr et al., 1998).
Of critical interest to practising child psychiatrists and
primary-care doctors, immunomodulatory therapies in
investigational protocols show promise in ameliorating
symptoms in the most severely symptomatic children
(Perlmutter et al., 1999). If replicated, it may be that the
secondary prevention of some children with early-onset
OCD like that of rheumatic fever itself will depend on
antibiotic prophylaxis (Garvey et al., 1999). Furthermore,
although open to a variety of methodological caveats,
Peterson et al. (2000) recently suggested that the
PANDAS phenotype may extend well beyond OCD and
tic disorders to just those conditions, especially attention
deficit hyperactivity disorder (ADHD) (Peterson et al.,
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2000), identified by Geller et al. (2001) in this Special
Section as being associated with early-onset OCD.
Information-processing models rooted in the appli-
cation of cognitive neuroscience to paediatric mental
illness are on the horizon across a variety of paediatric
anxiety disorders (Pine and Grun, 1999). Staying with
OCD, progress in understanding the functional neuro-
anatomy and pharmacoanatomy of paediatric OCD is
farther advanced than any other paediatric neuro-
psychiatric illness (March and Leonard, 1998). David
Rosenberg from Wayne State University in Detroit has
been a pioneer in using the tools of neuroimaging,
particularly structural and functional MRI and MRS to
disentangle the pathobiology of OCD (Rosenberg and
Keshavan, 1998). Introducing new data on the impact of
treatment on neural function, Rosenberg et al. (2001)
describe an integrated series of neurobiological studies
conducted largely in his laboratory that provide a
developmentally sensitive test of the hypothesis that
neurodevelopmental abnormalities of ventral prefrontal-
striatal-thalamo-cortical circuits may be involved in and
contribute to the aetiology and presentation of the
OCD in youth.
With a rapidly growing literature on the pharmaco-
kinetics of other compounds, such as the serotonin
reuptake inhibitors (Alderman et al., 1998), it is clear that
children and adolescents have much in common but also
show interesting differences from adults in drug ab-
sorption, disposition, metabolism and excretion (Vitiello
and Jensen, 1995). Similarly, an emerging literature on the
risk for drug–drug interactions is beginning to inform
clinical practice, although much remains to be learned
(Leonard et al., 1997). In this regard, because data about
drug safety and efficacy in adults can rarely be ex-
trapolated to children, there is no substitute for greatly
increased attention to pharmacodynamic (PD) and
pharmacokinetic (PK) studies in paediatric psycho-
pharmacological research (Vitiello and Jensen, 1997).
Given a wide range of new and reformulated psycho-
stimulants about to hit the ADHD market in the USA and,
presumably, Europe (see, for example, Kimko et al., 1999 ;
Modi et al., 2000), and the short time–response profile of
most psychostimulants, PK and PD studies of these
compounds are of particular relevance to clinical practice
(Greenhill et al., 1999). Nonetheless, despite the fact that
there is no better studied condition in all of psychiatry
irrespective of age than ADHD (Swanson, 1993), we still
lack basic PK}PD data on the relationship of stimulant
dose, serum level and behavioural}symptomatic out-
comes in children treated with methylphenidate, the most
commonly prescribed psychostimulant in youth (Jensen et
al., 1999a ; Kimko et al., 1999). While far from answering
this question fully, Greenhill et al. (2001) report a novel
PK}PD study of methylphenidate in a sample of ADHD
boys. As expected, motor performance errors and dose
proved to be inversely related ; conversely, while plasma
levels and dose were linearly related, plasma level and
response were not significantly correlated, implying that
the time to maximum concentration (T
max
) may be more
critical than the maximum concentration (C
max
) itself or
the area under the curve (AUC) in predicting response.
Importantly, in contrast to recent PD studies suggesting
subtle single dose tolerance effects (Swanson et al., 1999),
PK and PD parameters did not change between acute and
maintenance drug-treatment phases, suggesting an ab-
sence of tolerance at least over the intermediate term
using conventional dosing strategies.
These are exciting times for paediatric psychiatry. The
interplay between clinical practice and research remains
rich and varied (Rutter, 1999). Advances in treatment
have been sound if not spectacular to the point that most
observers now agree that translating research findings
regarding treatments that work into clinical practice is the
key to improving the public health of mentally ill children
and adolescents (Hoagwood et al., 1995). Progress has not
only come in psychopharmacology, which now has its
own journal, the Journal of Child and Adolescent Psycho-
pharmacology, but also in cognitive–behavioural psycho-
therapy (CBT), which in many cases shows far more
empirical support than other available treatments (March,
2000). CBT meshes nicely with developmentally sound
neurobehavioural approaches to paediatric mental illness
in which psychopathology can be seen as analogous to a
learning disability mediated by dysfunction in highly
conserved central nervous system information processes.
To the extent that symptom relief occurs, it can be
assumed that a reduction in symptoms reflects concurrent
changes (e.g. learning) in the central nervous system.
Looked at this way, the cognitive behavioural treatment
of paediatric mental illness can be thought of as partially
analogous to the treatment of juvenile-onset diabetes,
with the caveat that the target organ, the brain, in the case
of major mental illness, requires interventions of much
greater complexity. Using OCD as the exemplar, treat-
ment for diabetes and OCD both involve medications,
which, in diabetes, might be insulin and in OCD, a
serotonin reuptake inhibitor. Each also involves crucial
psychosocial interventions that work in part by biasing
the somatic substrate of the disorder toward more normal
function. In diabetes, the psychosocial treatment of choice
is diet and exercise, and in OCD, CBT. Working with
Nili Benazon and her colleague, David Rosenberg, we
have very preliminary data (unpublished) using MRS
suggesting that the pattern of response for children
responding to paroxetine may differ from those
responding to CBT. If this holds true, then the com-
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bination of CBT and pharmacotherapy (but only if
supported by evidence from comparative treatment trials)
may be more effective than monotherapy alone. While the
treatment of OCD and other paediatric neurobehavioural
illnesses within the medical model is far from fully
realized, the ground has been prepared for an evidence-
based approach to both training and clinical practice (cf.
the Institute on Evidence-based Medicine that Peter
Szmatari from McMaster University in Ontario, Canada,
and one of us (J. S. March) conducted at the year 2000
Annual Meeting of the American Academy of Child
and Adolescent Psychiatry).
Until recently, the National Institute of Mental Health
(NIMH) has supported most of the research conducted in
the USA on the biological bases of childhood mental
illness and on the effects of treatment and preventive
interventions for children and adolescents. Thus, over the
years, the NIMH has funded studies in a broad array of
conditions, including the efficacy of stimulants and
tricyclics in attention ADHD, of tricyclics and fluoxetine
in depression, and of neuroleptics in Tourette’s disorder.
Fortunately, the context of paediatric psychopharma-
cology in the USA has now substantially changed. In
response to enabling legislation (Laughren, 1996), the
pharmaceutical industry is now showing greater interest
in developing psychotropic medications for paediatric
use. Specifically, federally enacted legislation (Food and
Drug Administration Modernization Act, November
1997) and new Food and Drug Administration (FDA)
regulations (FDA, 1998) have provided powerful in-
centives to the pharmaceutical industry for studying
the effects of medication in children. As a consequence
of these initiatives, more than 100 new studies of
paediatric age have been started, of which 10 focus on
psychotropic medications. Considering the new interest
of industry in child psychopharmacology, NIMH has
redirected its efforts to areas that remain understudied
and still in need of expansion because of their considerable
clinical relevance and public health importance. Among
these areas are : (1) the study of the effectiveness of
treatments (i.e. treatment effects in usual conditions of
clinical practice, as opposed to ideal experimental
conditions of ‘ efficacy ’ studies) ; (2) the direct comparison
of different treatment modalities (e.g. pharmacotherapy
vs. psychotherapy vs. combined treatment) ; (3) research
on treatments for disorders such as autism, bipolar illness
and schizophrenia ; (4) research on treatments for youths
with co-morbid disorders ; (5) study of long-term effects
of treatments on functional parameters of clinical interest ;
and (6) assessment of safety of treatments, especially over
the long term.
One of the major obstacles to conducting multi-site
clinical trials in children is the limitation of the research
infrastructure. To address this deficit, in the last 4 years,
NIMHhas established a network of research units devoted
to paediatric psychopharmacology. Currently, there are 7
units at qualified academic sites, with several others
connected to these units as collaborating sites on various
protocols. Three current studies funded on the NIMH-
funded Research Units of Pediatric Psychopharmacology
network illustrate the point : (1) a study of fluvoxamine vs.
placebo in anxious children and adolescents in which
approx. 70% of the medicated group and only 30% of
the placebo group responded to treatment (RUPP
Cooperative Group, In Press) ; (2) a current treatment
addition study of fluvoxamine vs. placebo on top of a
stable psychostimulant in ADHD comorbid with anxiety
again in children ; and (3) an initiative to develop and test
an empirically derived patient and clinician report form
for ascertaining adverse events.
In this regard, substantial progress in developing
psychosocial and psychopharmacological monotherapies
has prepared the way for large comparative treatment
trials in samples that are reasonably representative of
clinical populations seen in clinical practice. For example,
the NIMH-funded collaborative Multimodal Treatment
Study of Children with ADHD (MTA) addressed a priori
questions about the individual and combined effects of
pharmacological and psychosocial (behavioural) treatment
for children aged 7–9 years with ADHD (Arnold et al.,
1997). Treatments that included the MTA medication
algorithm – Combination (Comb) and Medication Man-
agement (MedMgt) – showed better outcomes than those
without, i.e. Behavioural Treatment (Beh) and Community
Comparison (CC), on outcome measures involving core
ADHD symptoms (MTA Cooperative Group, 1999b).
On other outcome measures, the pattern of response was
slightly different : for internalizing behaviours, unimodal
treatments (MedMgt, Beh) did not differ significantly and,
in several instances, Comb proved superior to Beh for
internalizing outcomes, whereas MedMgt did not. For
example, parent report of a child’s anxiety disorder on the
Diagnostic Interview for Children moderated outcome for
core ADHD, internalizing, and anxiety symptoms (MTA
Cooperative Group, 1999a). For participants with anxiety
disorders, Beh was significantly superior to CC and no
longer different from MedMgt and Comb on some
measures. Thus, the presence of anxiety disorder in the
MTA sample did not appear to predict a worse response
to medication and did predict relatively better response to
behavioural treatment strategies. More detailed analyses
using hierarchical linear models (Bryk and Raudenbush,
1992) demonstrated that this effect, which was clinically
significant and did not depend on the presence of
intercurrent conduct problems, probably reflected the
impact of Beh on affectively negative behaviours oc-
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curring between parent and child (March et al., In Press).
Importantly, we are currently conducting NIMH-funded
comparative treatment trials in paediatric OCD and in
adolescent depression, with the latter – the Treatment of
Adolescent Depression Study (TADS; for information,
see http :}}www.nimh.nih.gov}studies}index.cfm) – the
flagship child and adolescent trial funded under the NIH
contract mechanism. In each case, these studies begin to
approach the question of which treatment is best for
which child with what set of predictive characteristics
(Jensen, 1999 ; March and Curry, 1998).
In 1983, Sir Michael Rutter opined that ‘while a good
deal is known about risk factors and areas amenable to
prevention, less is known about how to intervene to bring
about desired results ’ (Rutter, 1983). With a caveat or two
(Clarke et al., 1995), the focus will likely remain on
treating mentally ill youth rather than on primary or even
secondary prevention strategies for the time being
(Harrington and Clark, 1998). To move from treatment
to prevention, a much more developmentally sensitive
sophisticated understanding of the neurobiology of
mental illness and of person and environment interactions
will be necessary. While we wait for the requisite high-risk
and genetic epidemiological investigations to bear fruit,
the developmental perspective concerning behavioural
neuroscience illustrated in the articles presented in this
Special Section of IJNP promises to add substantially to
both the nosology and rational treatment of mentally ill
children and adolescents.
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